$ISTA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ISTA PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ISTA PHARMACEUTICALS INC. Get notifications about new insider transactions in ISTA PHARMACEUTICALS INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 11 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Payment of Exercise | F | 9.08 | 1,219 | 11,069 | 38,381 | 39.6 K to 38.4 K (-3.08 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Buy | M | 4.58 | 2,416 | 11,065 | 39,600 | 37.2 K to 39.6 K (+6.50 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Payment of Exercise | F | 9.08 | 2,995 | 27,195 | 37,184 | 40.2 K to 37.2 K (-7.45 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Buy | M | 3.63 | 7,492 | 27,196 | 40,179 | 32.7 K to 40.2 K (+22.92 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Payment of Exercise | F | 9.08 | 7,814 | 70,951 | 32,687 | 40.5 K to 32.7 K (-19.29 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Buy | M | 3.71 | 19,125 | 70,954 | 40,501 | 21.4 K to 40.5 K (+89.47 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 7.43 | 13,717 | 101,917 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 6.82 | 2,212 | 15,086 | 25,542 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 6.77 | 17,203 | 116,464 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 5.40 | 65,867 | 355,682 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 4.46 | 18,903 | 84,307 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 3.63 | 11,262 | 40,881 | 20,564 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | M | 1.04 | 16,649 | 17,315 | 8,814 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 1,661 | 15,082 | 185,020 | 186.7 K to 185 K (-0.89 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 6.82 | 2,212 | 15,086 | 186,681 | 184.5 K to 186.7 K (+1.20 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 4,502 | 40,878 | 184,469 | 189 K to 184.5 K (-2.38 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 3.63 | 11,262 | 40,881 | 188,971 | 177.7 K to 189 K (+6.34 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 1,907 | 17,316 | 177,709 | 179.6 K to 177.7 K (-1.06 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 1.04 | 16,649 | 17,315 | 179,616 | 163 K to 179.6 K (+10.22 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 11,224 | 101,914 | 162,967 | 174.2 K to 163 K (-6.44 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 7.43 | 13,717 | 101,917 | 174,191 | 160.5 K to 174.2 K (+8.55 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 12,826 | 116,460 | 160,474 | 173.3 K to 160.5 K (-7.40 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 6.77 | 17,203 | 116,464 | 173,300 | 156.1 K to 173.3 K (+11.02 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 39,172 | 355,682 | 156,097 | 195.3 K to 156.1 K (-20.06 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 5.40 | 65,867 | 355,682 | 195,269 | 129.4 K to 195.3 K (+50.90 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Payment of Exercise | F | 9.08 | 9,285 | 84,308 | 129,402 | 138.7 K to 129.4 K (-6.69 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | M | 4.46 | 18,903 | 84,307 | 138,687 | 119.8 K to 138.7 K (+15.78 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | M | 7.43 | 12,415 | 92,243 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | M | 6.77 | 14,154 | 95,823 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | M | 4.46 | 22,744 | 101,438 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | M | 3.63 | 3,103 | 11,264 | 36,758 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | M | 3.49 | 28,653 | 99,999 | 0 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | M | 1.04 | 17,051 | 17,733 | 30,685 | |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Payment of Exercise | F | 9.08 | 1,241 | 11,268 | 541,116 | 542.4 K to 541.1 K (-0.23 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Buy | M | 3.63 | 3,103 | 11,264 | 542,357 | 539.3 K to 542.4 K (+0.58 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Payment of Exercise | F | 9.08 | 1,953 | 17,733 | 539,254 | 541.2 K to 539.3 K (-0.36 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Buy | M | 1.04 | 17,051 | 17,733 | 541,207 | 524.2 K to 541.2 K (+3.25 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Payment of Exercise | F | 9.08 | 10,159 | 92,244 | 524,156 | 534.3 K to 524.2 K (-1.90 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Buy | M | 7.43 | 12,415 | 92,243 | 534,315 | 521.9 K to 534.3 K (+2.38 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Payment of Exercise | F | 9.08 | 10,553 | 95,821 | 521,900 | 532.5 K to 521.9 K (-1.98 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Buy | M | 6.77 | 14,154 | 95,823 | 532,453 | 518.3 K to 532.5 K (+2.73 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Payment of Exercise | F | 9.08 | 11,013 | 99,998 | 518,299 | 529.3 K to 518.3 K (-2.08 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Buy | M | 3.49 | 28,653 | 99,999 | 529,312 | 500.7 K to 529.3 K (+5.72 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Payment of Exercise | F | 9.08 | 11,172 | 101,442 | 500,659 | 511.8 K to 500.7 K (-2.18 %) |
May 10 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Buy | M | 4.46 | 22,744 | 101,438 | 511,831 | 489.1 K to 511.8 K (+4.65 %) |
Apr 27 2012 | ISTA | ISTA PHARMACEUTICA ... | ROE WAYNE I | Director | Payment of Exercise | F | 5.88 | 374 | 2,199 | 1,126 | 1.5 K to 1.1 K (-24.93 %) |
Mar 23 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | J | 0.00 | 674,116 | 0 | 3,796,792 | 4.5 M to 3.8 M (-15.08 %) |
Mar 16 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.59 | 4,373 | 37,564 | 4,470,908 | 4.5 M to 4.5 M (-0.10 %) |
Mar 16 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.52 | 145,573 | 1,239,685 | 4,475,281 | 4.6 M to 4.5 M (-3.15 %) |
Mar 16 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.58 | 157,043 | 1,347,822 | 4,620,854 | 4.8 M to 4.6 M (-3.29 %) |
Mar 16 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.58 | 130,256 | 1,117,727 | 4,777,897 | 4.9 M to 4.8 M (-2.65 %) |
Mar 16 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.70 | 28,571 | 248,551 | 4,908,153 | 4.9 M to 4.9 M (-0.58 %) |
Mar 05 2012 | ISTA | ISTA PHARMACEUTICA ... | Davis Glenn Eugene | VP Legal, Chief Com ... | Sell | D | 8.23 | 1,222 | 10,057 | 27,983 | 29.2 K to 28 K (-4.18 %) |
Mar 12 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.38 | 17,391 | 145,658 | 4,945,470 | 5 M to 4.9 M (-0.35 %) |
Mar 12 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.30 | 4,373 | 36,302 | 4,962,861 | 5 M to 5 M (-0.09 %) |
Mar 12 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 8.30 | 200,886 | 1,667,695 | 4,967,234 | 5.2 M to 5 M (-3.89 %) |
Mar 02 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | J | 0.00 | 1,002,553 | 0 | 5,168,120 | 6.2 M to 5.2 M (-16.25 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Sell | D | 8.15 | 3,332 | 27,156 | 489,087 | 492.4 K to 489.1 K (-0.68 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Sell | D | 8.17 | 3,333 | 27,231 | 492,419 | 495.8 K to 492.4 K (-0.67 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | GARRETT MARVIN J | Vice President, QC, ... | Sell | D | 8.15 | 1,046 | 8,525 | 62,801 | 63.8 K to 62.8 K (-1.64 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | GARRETT MARVIN J | Vice President, QC, ... | Sell | D | 8.17 | 1,057 | 8,636 | 63,847 | 64.9 K to 63.8 K (-1.63 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | MCGINLEY KATHLEEN | VP, HR and Corp. Fa ... | Sell | D | 8.15 | 837 | 6,822 | 59,852 | 60.7 K to 59.9 K (-1.38 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | MCGINLEY KATHLEEN | VP, HR and Corp. Fa ... | Sell | D | 8.17 | 889 | 7,263 | 60,689 | 61.6 K to 60.7 K (-1.44 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | MCMULLIN KIRK | VP, Operations | Sell | D | 8.15 | 836 | 6,813 | 72,335 | 73.2 K to 72.3 K (-1.14 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | MCMULLIN KIRK | VP, Operations | Sell | D | 8.17 | 889 | 7,263 | 73,171 | 74.1 K to 73.2 K (-1.20 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | McNamara Timothy | VP Clinical Researc ... | Sell | D | 8.15 | 837 | 6,822 | 54,753 | 55.6 K to 54.8 K (-1.51 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | McNamara Timothy | VP Clinical Researc ... | Sell | D | 8.17 | 889 | 7,263 | 55,590 | 56.5 K to 55.6 K (-1.57 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Sell | D | 8.15 | 1,066 | 8,688 | 119,784 | 120.9 K to 119.8 K (-0.88 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Sell | D | 8.17 | 1,146 | 9,363 | 120,850 | 122 K to 120.9 K (-0.94 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | MITRO THOMAS A | VP, Sales & Marketi ... | Sell | D | 8.15 | 1,327 | 10,815 | 115,202 | 116.5 K to 115.2 K (-1.14 %) |
Feb 09 2012 | ISTA | ISTA PHARMACEUTICA ... | MITRO THOMAS A | VP, Sales & Marketi ... | Sell | D | 8.17 | 1,167 | 9,534 | 116,529 | 117.7 K to 116.5 K (-0.99 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Sell | D | 8.22 | 3,332 | 27,389 | 495,752 | 499.1 K to 495.8 K (-0.67 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Sell | D | 8.18 | 3,692 | 30,201 | 499,084 | 502.8 K to 499.1 K (-0.73 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | Davis Glenn Eugene | VP Legal, Chief Com ... | Sell | D | 8.18 | 314 | 2,569 | 29,205 | 29.5 K to 29.2 K (-1.06 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | GARRETT MARVIN J | Vice President, QC, ... | Sell | D | 8.18 | 837 | 6,847 | 64,904 | 65.7 K to 64.9 K (-1.27 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | MCGINLEY KATHLEEN | VP, HR and Corp. Fa ... | Sell | D | 8.22 | 837 | 6,880 | 61,578 | 62.4 K to 61.6 K (-1.34 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | MCGINLEY KATHLEEN | VP, HR and Corp. Fa ... | Sell | D | 8.18 | 837 | 6,847 | 62,415 | 63.3 K to 62.4 K (-1.32 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | MCMULLIN KIRK | VP, Operations | Sell | D | 8.22 | 837 | 6,880 | 74,060 | 74.9 K to 74.1 K (-1.12 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | MCMULLIN KIRK | VP, Operations | Sell | D | 8.18 | 837 | 6,847 | 74,897 | 75.7 K to 74.9 K (-1.11 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | McNamara Timothy | VP Clinical Researc ... | Sell | D | 8.18 | 837 | 6,847 | 56,479 | 57.3 K to 56.5 K (-1.46 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | MITRO THOMAS A | VP, Sales & Marketi ... | Sell | D | 8.18 | 1,748 | 14,299 | 117,696 | 119.4 K to 117.7 K (-1.46 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Sell | D | 8.22 | 942 | 7,743 | 121,996 | 122.9 K to 122 K (-0.77 %) |
Feb 06 2012 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Sell | D | 8.18 | 942 | 7,706 | 122,938 | 123.9 K to 122.9 K (-0.76 %) |
Feb 03 2012 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | J | 0.00 | 1,002,553 | 0 | 6,170,673 | 7.2 M to 6.2 M (-13.98 %) |
Feb 01 2012 | ISTA | ISTA PHARMACEUTICA ... | Davis Glenn Eugene | VP Legal, Chief Com ... | Sell | D | 8.10 | 314 | 2,543 | 29,519 | 29.8 K to 29.5 K (-1.05 %) |
Dec 07 2011 | ISTA | ISTA PHARMACEUTICA ... | MCGRAW BENJAMIN F III | Director | Option Exercise | A | 3.89 | 20,000 | 77,800 | 20,000 | |
Dec 07 2011 | ISTA | ISTA PHARMACEUTICA ... | PERLMAN ANDREW J | Director | Option Exercise | A | 3.89 | 20,000 | 77,800 | 20,000 | |
Dec 07 2011 | ISTA | ISTA PHARMACEUTICA ... | MITCHELL DEAN J | Director | Option Exercise | A | 3.89 | 20,000 | 77,800 | 20,000 | |
Dec 07 2011 | ISTA | ISTA PHARMACEUTICA ... | HUTT PETER BARTON | Director | Option Exercise | A | 3.89 | 20,000 | 77,800 | 20,000 | |
Dec 07 2011 | ISTA | ISTA PHARMACEUTICA ... | WILLIAMS RICHARD C | Director | Option Exercise | A | 3.89 | 20,000 | 77,800 | 20,000 | |
Dec 07 2011 | ISTA | ISTA PHARMACEUTICA ... | ROE WAYNE I | Director | Option Exercise | A | 3.89 | 20,000 | 77,800 | 20,000 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | A | 0.00 | 13,612 | 0 | 13,612 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | A | 0.00 | 13,613 | 0 | 13,613 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | A | 3.75 | 172,775 | 647,906 | 172,775 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Option Exercise | A | 3.75 | 236,350 | 886,313 | 236,350 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Grant | A | 0.00 | 63,650 | 64 | 502,776 | 439.1 K to 502.8 K (+14.49 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | ANIDO VICENTE JR | President & CEO | Grant | A | 0.00 | 25,686 | 26 | 439,126 | 413.4 K to 439.1 K (+6.21 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | GARRETT MARVIN J | Vice President, QC, ... | Option Exercise | A | 3.75 | 104,875 | 393,281 | 104,875 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | GARRETT MARVIN J | Vice President, QC, ... | Grant | A | 0.00 | 23,250 | 23 | 65,741 | 42.5 K to 65.7 K (+54.72 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | McNamara Timothy | VP Clinical Researc ... | Option Exercise | A | 3.75 | 95,625 | 358,594 | 95,625 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | McNamara Timothy | VP Clinical Researc ... | Grant | A | 0.00 | 21,250 | 21 | 57,316 | 36.1 K to 57.3 K (+58.92 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | MCMULLIN KIRK | VP, Operations | Option Exercise | A | 3.75 | 100,000 | 375,000 | 100,000 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | MCMULLIN KIRK | VP, Operations | Grant | A | 0.00 | 22,250 | 22 | 75,734 | 53.5 K to 75.7 K (+41.60 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Option Exercise | A | 3.75 | 122,875 | 460,781 | 122,875 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Grant | A | 0.00 | 27,375 | 27 | 123,880 | 96.5 K to 123.9 K (+28.37 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | MITRO THOMAS A | VP, Sales & Marketi ... | Option Exercise | A | 3.75 | 125,000 | 468,750 | 125,000 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | MITRO THOMAS A | VP, Sales & Marketi ... | Grant | A | 0.00 | 27,875 | 28 | 119,444 | 91.6 K to 119.4 K (+30.44 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | MCGINLEY KATHLEEN | VP, HR and Corp. Fa ... | Option Exercise | A | 3.75 | 100,000 | 375,000 | 100,000 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | MCGINLEY KATHLEEN | VP, HR and Corp. Fa ... | Grant | A | 0.00 | 22,250 | 22 | 63,252 | 41 K to 63.3 K (+54.27 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Option Exercise | A | 3.75 | 1,940 | 7,275 | 1,940 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Option Exercise | A | 3.75 | 29,935 | 112,256 | 29,935 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Grant | A | 0.00 | 8,083 | 8 | 21,376 | 13.3 K to 21.4 K (+60.81 %) |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | Davis Glenn Eugene | VP Legal, Chief Com ... | Option Exercise | A | 3.75 | 33,750 | 126,563 | 33,750 | |
Dec 02 2011 | ISTA | ISTA PHARMACEUTICA ... | Davis Glenn Eugene | VP Legal, Chief Com ... | Grant | A | 0.00 | 7,500 | 8 | 29,833 | 22.3 K to 29.8 K (+33.58 %) |
Sep 12 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 4.10 | 1,400 | 5,741 | 7,278,797 | 7.3 M to 7.3 M (-0.02 %) |
Sep 15 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 4.07 | 4,322 | 17,602 | 7,173,226 | 7.2 M to 7.2 M (-0.06 %) |
Sep 15 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 3.94 | 22,576 | 88,945 | 7,177,548 | 7.2 M to 7.2 M (-0.31 %) |
Sep 15 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 4.03 | 78,673 | 317,383 | 7,200,124 | 7.3 M to 7.2 M (-1.08 %) |
Sep 06 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 4.14 | 46,761 | 193,403 | 7,280,197 | 7.3 M to 7.3 M (-0.64 %) |
Sep 06 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | S | 4.31 | 5,800 | 24,988 | 7,326,958 | 7.3 M to 7.3 M (-0.08 %) |
Aug 15 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | P | 4.30 | 30 | 129 | 96,505 | 96.5 K to 96.5 K (+0.03 %) |
Aug 15 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | P | 4.29 | 400 | 1,716 | 96,475 | 96.1 K to 96.5 K (+0.42 %) |
Aug 15 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | Chief Financial Off ... | Buy | P | 4.28 | 2,070 | 8,860 | 96,075 | 94 K to 96.1 K (+2.20 %) |
Aug 12 2011 | ISTA | ISTA PHARMACEUTICA ... | Drazba Brian G. | VP, Finance & CAO | Buy | P | 4.38 | 1,500 | 6,567 | 13,293 | 11.8 K to 13.3 K (+12.72 %) |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | M | 4.46 | 29,097 | 129,773 | 0 | |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | M | 3.63 | 12,033 | 43,680 | 3,141 | |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Option Exercise | M | 1.04 | 21,537 | 22,398 | 0 | |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Payment of Exercise | F | 11.26 | 6,870 | 77,356 | 94,005 | 100.9 K to 94 K (-6.81 %) |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | M | 3.63 | 12,033 | 43,680 | 100,875 | 88.8 K to 100.9 K (+13.54 %) |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Payment of Exercise | F | 11.26 | 9,159 | 103,130 | 88,842 | 98 K to 88.8 K (-9.35 %) |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | M | 1.04 | 21,537 | 22,398 | 98,001 | 76.5 K to 98 K (+28.17 %) |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Payment of Exercise | F | 11.26 | 17,971 | 202,353 | 76,464 | 94.4 K to 76.5 K (-19.03 %) |
May 12 2011 | ISTA | ISTA PHARMACEUTICA ... | SILVERNAIL LAUREN P | CFO | Buy | M | 4.46 | 29,097 | 129,773 | 94,435 | 65.3 K to 94.4 K (+44.53 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 135,036 | 1,431,382 | 551,099 | 686.1 K to 551.1 K (-19.68 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 83,814 | 888,428 | 342,061 | 425.9 K to 342.1 K (-19.68 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 39,916 | 423,110 | 162,917 | 202.8 K to 162.9 K (-19.68 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.60 | 26,375 | 279,575 | 107,655 | 134 K to 107.7 K (-19.68 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 52,551 | 551,786 | 686,135 | 738.7 K to 686.1 K (-7.11 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 32,616 | 342,468 | 425,875 | 458.5 K to 425.9 K (-7.11 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 15,535 | 163,118 | 202,833 | 218.4 K to 202.8 K (-7.11 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.50 | 10,265 | 107,783 | 134,030 | 144.3 K to 134 K (-7.11 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.54 | 478,946 | 5,048,091 | 738,686 | 1.2 M to 738.7 K (-39.33 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.54 | 297,290 | 3,133,437 | 458,491 | 755.8 K to 458.5 K (-39.34 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.52 | 328,995 | 3,461,027 | 218,368 | 547.4 K to 218.4 K (-60.11 %) |
May 06 2011 | ISTA | ISTA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 10.52 | 211,717 | 2,227,263 | 144,295 | 356 K to 144.3 K (-59.47 %) |
Apr 15 2011 | ISTA | ISTA PHARMACEUTICA ... | CREDIT SUISSE AG/ | 10% Owner | Sell | J | 0.00 | 1,003,825 | 0 | 7,332,758 | 8.3 M to 7.3 M (-12.04 %) |
Apr 15 2011 | ISTA | ISTA PHARMACEUTICA ... | LAPORTE KATHLEEN | Director | Sell | J | 10.49 | 1,235,419 | 12,954,604 | 7,109,096 | 8.3 M to 7.1 M (-14.81 %) |
Apr 13 2011 | ISTA | ISTA PHARMACEUTICA ... | LAPORTE KATHLEEN | Director | Option Exercise | X | 1.41 | 1,615,385 | 2,277,693 | 0 | |
Apr 13 2011 | ISTA | ISTA PHARMACEUTICA ... | LAPORTE KATHLEEN | Director | Option Exercise | P | 1.41 | 1,615,385 | 2,277,693 | 1,615,385 | |
Apr 13 2011 | ISTA | ISTA PHARMACEUTICA ... | LAPORTE KATHLEEN | Director | Sell | S | 10.52 | 216,526 | 2,277,854 | 8,344,515 | 8.6 M to 8.3 M (-2.53 %) |